12 results match your criteria concomitant sjw

  • Page 1 of 1

Clinical risks of St John's Wort (Hypericum perforatum) co-administration.

Expert Opin Drug Metab Toxicol 2017 Oct 13;13(10):1047-1062. Epub 2017 Sep 13.

d Toxicology and Diseases Group, Pharmaceutical Sciences Research Center , Tehran University of Medical Sciences , Tehran , Iran.

Introduction: St. John's wort (SJW) is a common medicinal herb used for the treatment of mild to moderate depression. Hyperforin, one of the chief components of SJW, plays an important role in the induction of cytochrome P450 enzymes (CYP) and P-glycoprotein transporter (P-gp), and therefore, affects the pharmacokinetics of various drugs. Read More

View Article and Full-Text PDF
October 2017

Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.

Curr Alzheimer Res 2013 Dec;10(10):1057-69

University of Magdeburg, Department of Neurology, Neurodegeneration Research Laboratory (NRL), Leipziger Str. 44, Bldg 64, 39120 Magdeburg, Germany.

Soluble β-amyloid peptides (Aβ) and small Aβ oligomers represent the most toxic peptide moieties recognized in brains affected by Alzheimer's disease (AD). Here we provide the first evidence that specific St. John's wort (SJW) extracts both attenuate Aβ-induced histopathology and alleviate memory impairments in APP-transgenic mice. Read More

View Article and Full-Text PDF
December 2013

The effect of St John's wort on the pharmacokinetics of docetaxel.

Clin Pharmacokinet 2014 Jan;53(1):103-10

Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands,

Background And Objective: St John's wort (SJW), a herbal antidepressant, is commonly used by cancer patients, and its component hyperforin is a known inducer of the cytochrome P450 (CYP) isoenzyme 3A4. Here, the potential pharmacokinetic interaction between SJW and the sensitive CYP3A4 substrate docetaxel was investigated.

Methods: In ten evaluable cancer patients, the pharmacokinetics of docetaxel (135 mg administered intravenously over 60 min) were compared before and after 14 days of supplementation with SJW (300 mg extract [Hyperiplant(®)] three times daily). Read More

View Article and Full-Text PDF
January 2014

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.

Cancer Treat Rev 2013 Nov 8;39(7):773-83. Epub 2013 Feb 8.

Utrecht University, Utrecht Institute for Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, The Netherlands.

The use of complementary and alternative medicines (CAM) by cancer patients is increasing. Concomitant use of CAM and anticancer drugs could lead to serious safety issues in patients. CAM have the potential to cause pharmacokinetic interactions with anticancer drugs, leading to either increased or decreased plasma levels of anticancer drugs. Read More

View Article and Full-Text PDF
November 2013

In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts.

Phytochemistry 2011 Oct 23;72(14-15):1814-20. Epub 2011 Jul 23.

Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence (COE) Program, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.

Extracts from St. John's Wort (SJW: Hypericum perforatum) have been used for the treatment of mild-to-moderate depression. In spite of the high therapeutic potential, orally administered SJW sometimes causes phototoxic skin responses. Read More

View Article and Full-Text PDF
October 2011

Hypericum perforatum L. (St John's wort) extract Ze 117 inhibits dopamine re-uptake in rat striatal brain slices. An implication for use in smoking cessation treatment?

Phytother Res 2010 Feb;24(2):249-51

Department of Pharmacology, University of Bern, Bern, Switzerland.

Classic synthetic antidepressant drugs, as well as St John's wort extract (SJW), directly inhibit the re-uptake of norepinephrine (NE) and/or serotonin (5-HT) into pre-synaptic axons. With chronic treatment they induce adaptive changes in a number of neurotransmitter receptors in synaptic membranes. The immediate effects of SJW Ze 117, an extract low in hyperforin content, on the specific dopamine (DA) uptake were studied in rat striatal brain slices and compared with the effects on NE and 5-HT uptake in rat cortical brain slices. Read More

View Article and Full-Text PDF
February 2010

Molecular mechanisms underlying St. John's wort drug interactions.

Curr Drug Metab 2008 Dec;9(10):1027-37

Institute of Pharmacy and Molecular Biotechnology, Ruprecht Karls University, Heidelberg, Germany.

The phytopharmaceutical agent St. John's wort (SJW) is currently under intense investigation. Studies of drug interactions resulting from concomitant use of SJW and conventional medication are of fundamental importance, since the use of SJW as a complementary and alternative medicine is highly popular. Read More

View Article and Full-Text PDF
December 2008

MDR- and CYP3A4-mediated drug-herbal interactions.

Life Sci 2006 Mar 25;78(18):2131-45. Epub 2006 Jan 25.

School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO 64110-2499, USA.

According to recent epidemiological reports, almost 40% of American population use complimentary and alternative medicine (CAM) during their lifetime. Patients detected with HIV or cancer often consume herbal products especially St. John's wort (SJW) for antidepressants in combination with prescription medicines. Read More

View Article and Full-Text PDF

Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.

Clin Pharmacol Ther 2005 Jul;78(1):25-33

Department of Internal Medicine VI, Clinial Pharmacology and Pharmacoepidemiology, University of Heidelberg, D-69120 Heidelberg, Germany.

Objectives: Constituents of St John's wort (SJW) in vivo induce the cytochrome P450 (CYP) isozymes 3A4, 2C9, and 2C19 but in vitro were shown to inhibit them. This study investigates both short- and long-term effects of SJW on the antifungal voriconazole, which is metabolized by these enzymes.

Methods: In a controlled, open-label study, single oral doses of 400 mg voriconazole were administered to 16 healthy men stratified for CYP2C19 genotype before and on day 1 and day 15 of concomitant SJW intake (300 mg LI 160 3 times daily). Read More

View Article and Full-Text PDF

No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.

Planta Med 2005 Apr;71(4):331-7

Institute of Clinical Pharmacology, University Medical Center Charité, Humboldt University, Berlin, Germany.

We evaluated the pharmacokinetic interaction between a low-hyperforin St John's wort (SJW) extract and alprazolam, caffeine, tolbutamide, and digoxin. Previous reports on other SJW products had shown remarkably decreased plasma concentrations of certain co-medicated drugs, which was attributed to an inducing effect of SJW on cytochrome P-450 (CYP) and p-glycoprotein (p-gp) activity. Two randomised, placebo-controlled studies were performed with 28 healthy volunteers (age 18 - 55 years) in each study. Read More

View Article and Full-Text PDF

[Consultation and survey for drug interaction in outpatients taking the medicines potentially interact with St. John's Wort].

Yakugaku Zasshi 2000 Dec;120(12):1435-40

Department of Pharmaceutical Sciences, Institute of Clinical Medicine, University of Tsukuba, 1-1-1, Ten-nodai, Tsukuba, Ibaraki 305-8575, Japan.

Ministry Health Welfare of Japan announced the caution for drug interaction of St. John's Wort (SJW), a herbal supplement occasionally used for depression, on May, 2000. Immediately after the announcement, we conducted drug consultation for outpatients prescribed the medicines potentially interacting with SJW. Read More

View Article and Full-Text PDF
December 2000

Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability.

Pharmacotherapy 2000 May;20(5):568-74

Department of Psychiatry, School of Pharmacy, University of Missouri-Kansas City, and Western Missouri Mental Health Center, 64108-2792, USA.

Despite its poorly described pharmacology, effectiveness, and safety, use of St. John's wort (SJW) is largely unsupervised and unexplored, and can potentially lead to adverse outcomes. We conducted a telephone survey of 43 subjects who had taken SJW to assess demographics, psychiatric and medical conditions, dosage, duration of use, reason for use, side effects, concomitant drugs, professional consultation, effectiveness, relapse, and withdrawal effects. Read More

View Article and Full-Text PDF
  • Page 1 of 1